跳至主要内容
临床试验/ACTRN12616001185459
ACTRN12616001185459已完成不适用

A Prospective Investigation of the Use of the Intuitive Robotic-Assisted Bronchoscope System (Safety and Feasibility Study) in patients with Pulmonary Nodules of Unknown Etiology

Intuitive Surgical0 个研究点目标入组 30 人开始时间: 2016年8月29日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • 1) Patients suitable for surgery or intervention, aged 18 years - 75 years
  • 2) Pulmonary nodule(s) (PN) due to suspected lung cancer or metastatic disease or nodule(s) of unknown etiology that require further diagnostic evaluation
  • 3) One or more soft tissue dominant pulmonary nodules between (and including) 10mm and 30 mm in largest dimension on axial plane
  • 4) Nodule completely surrounded by at least 5 mm lung parenchyma, does not touch the hilum or mediastinum, is not associated with adenopathy, atelectasis, or pleural effusion, and the proximal nodule margin (leading edge facing the bronchus & catheter) is more than 1.5 cm distant to the visceral pleura
  • 5) Patients with a moderate to high risk of lung cancer based on clinical, demographic and radiologic information using risk prediction algorithms (as described in the review article of Lam and Tammemagi)
  • 6) PN accessible bronchoscopically on planning CT reconstruction (within 3 cm proximity to PN)
  • 7) Patient able to understand and adhere to study requirements
  • 8) Patient able to provide and sign informed consent
  • 9) Patient not legally incapacitated

排除标准

  • 1) An inability to tolerate bronchoscopy under endotracheal intubation and general anesthesia.
  • 2) ASA class greater than or equal to 3
  • 3) PN touches the pulmonary hilum or mediastinum, or is associated with adenopathy, lobar atelectasis, or pleural effusion
  • 4) Central PN’s located within the first 3 airway generations (segmental airways, B1-10)
  • 5) The airway leading to the target lesion arises from an aberrant accessory tracheal bronchus
  • 6) Continuous use of anticoagulants (eg, heparin, warfarin) or antiplatelet agents (e.g. Cyclooxygenase Inhibitors (Aspirin), ADP-Receptor inhibitors (Clopidogrel), GP-IIB/IIIA- inhibitors (Abciximac), fish oil, etc) which cannot be discontinued.
  • 7) Uncorrectable coagulopathy or bleeding diathesis
  • 8) Platelet dysfunction or platelet count less than 100×10 to the 9th power
  • 9) History of major bleeding with bronchoscopy
  • 10) Pulmonary hypertension with mean Pulmonary Arterial Pressure (PAP) greater than 25 mm
  • 11) Moderate-to-severe pulmonary fibrosis
  • 12) Severe respiratory insufficiency or hypoxia, moderate-to-severe hypoxemia or any degree of hypercarbia
  • 13) One or more bullae greater than 1 cm located in close vicinity (less than 1cm) of target PN
  • 14) Giant bullae within the same lobe of the target PN
  • 15) Partial tracheal obstruction or obstruction of the superior vena cava
  • 16) Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy for example:
  • 16a) greater than Stage 3 heart failure (NY-Heart Failure Classification)
  • 16b) Unstable hemodynamic status including
  • 16c) Uncontrolled dysrhythmias
  • 16d) History of ventricular arrhythmias
  • 16e) Uncontrolled Hypertension
  • (Blood Pressure systolic greater than 200mmHg, Blood Pressure diastolic greater than 120mmHg)
  • 16f) Unstable Angina
  • 16g) Myocardial infarction within 6 months
  • 16h) Severe cachexia, debility and malnutrition
  • 16i) Acute Renal or Liver Failure
  • 17) Ongoing systemic acute or chronic infection
  • 18) Pneumonia or acute bronchitis within 3 month of the procedure
  • 19) Lung abscess
  • 20) White Blood Cell (WBC) Count less than 2000 or greater than 20,000
  • 21) Recent head injury or increased intracranial pressure
  • 22) Contraindication to general anesthesia
  • 23) Exposure to radiation treatment or chemotherapy within 3 months prior to the IROB procedure
  • 24) Participation in any other study in last 30 days
  • 25) Prior thoracic surgery on the same side of the lung as the PN or pneumonectomy of the contralateral lung
  • 26) Patients who are pregnant or lactating
  • 27) Patients with known intrapulmonary metastases of extrapulmonary cancer/tumors
  • 28) Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
  • 29) Persons held in an institution by legal or official order, or part of vulnerable population (i.e. mentally disabled)
  • 30) Known allergy, sensitivity or previous allergic reaction to ortho-phthalaldehyde (OPA)

研究者

相似试验